Amy VanDuyn, Senior Vice President of Human Resources at Phreesia, Inc. (NYSE:PHR), a $1.2 billion healthcare software company that has grown revenue by 22% year-over-year, recently sold 25,447 shares of the company's common stock, valued at approximately $532,559. The shares were sold at a weighted average price of $20.9282, with transaction prices ranging from $20.665 to $21.375. Following this sale, VanDuyn retains ownership of 93,470 shares. This transaction was part of a Rule 10b5-1 trading plan adopted in April 2024. According to InvestingPro analysis, Phreesia appears undervalued based on its Fair Value estimate, with analysts setting price targets between $23 and $34. The company is scheduled to report earnings in just 4 days, which could be a significant catalyst for the stock.Get deeper insights into insider trading patterns and more with InvestingPro, featuring exclusive ProTips and comprehensive analysis of 1,400+ stocks.
In other recent news, Phreesia, a healthcare software company, has been the center of attention among several financial firms following its strong Q2 results. The company reported a 19% year-over-year increase in revenue, totaling $102.1 million. The adjusted EBITDA rose to $6.5 million, marking an $18 million improvement from the previous year. DA Davidson reaffirmed its Buy rating for Phreesia, anticipating strong EBITDA guidance for FY26. Similarly, Baird raised its price target for Phreesia to $34, citing strong growth prospects, while Truist Securities increased its price target to $31, highlighting expected EBITDA strength and revenue growth. Piper Sandler maintained its price target at $30, expressing optimism about the company's financial performance. Canaccord Genuity also retained its $34 price target, emphasizing the company's operational efficiency and focus on long-term profitability. These recent developments shed light on Phreesia's strong financial performance and the positive outlook from various financial firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.